Valeant Pharmaceuticals said it plans to take its $53 billion acquisition bid directly to Allergan shareholders later this week, launching a tender offer after repeatedly being rebuffed by Allergan's board.
from WSJ.com: US Business http://ift.tt/U6v5n4
via IFTTT
from WSJ.com: US Business http://ift.tt/U6v5n4
via IFTTT
No comments:
Post a Comment